Clincosm LogoSign in Get a demo

Safety Study of Vx006 Vaccine in Solid Tumor Patients

Sponsor
Vaxon Biotech (Industry)
Overall Status
Completed
CT.gov ID
NCT02289196
Collaborator
(none)
23
Enrollment
3
Locations
4
Arms
38
Duration (Months)
7.7
Patients Per Site
0.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Patients with histologically proven malignancy with documented disease control (objective response or stable disease) or Not Evaluable Disease (NED) expectancy > 6 months; only HLA-A*02 positive patients.

The primary objective of the trial is to compare safety and tolerability of four different doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses of the Vx-006.

Condition or Disease Intervention/Treatment Phase
  • Drug: Vx-006: 0,5mg
  • Drug: Vx-006: 1mg
  • Drug: Vx-006: 5mg
  • Drug: Vx-006: 10mg
 Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
23 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg, 5mg and 10mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours
Study Start Date :
Mar 1, 2014
Actual Primary Completion Date :
Oct 1, 2014
Actual Study Completion Date :
May 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Vx-006: 0,5mg

Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks

Drug: Vx-006: 0,5mg
Experimental: Vx-006: 1mg

Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks

Drug: Vx-006: 1mg
Experimental: Vx-006: 5mg

Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks

Drug: Vx-006: 5mg
Experimental: Vx-006: 10mg

Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks

Drug: Vx-006: 10mg

Outcome Measures

Primary Outcome Measures

  1. Adverse event number by treatment group as a measure of safety and tolerability [18 Weeks]

    The following parameters of safety and tolerability will be assessed: Physical examination and vital signs (blood pressure, pulse rate, body temperature, weight, height (only at baseline), Electrocardiogram, Adverse event evaluation, Eastern Cooperative Oncology Group (ECOG) performance status, Clinical laboratory evaluation: haematology and clinical chemistry Collection of concomitant medication

Secondary Outcome Measures

  1. Immune response evaluation by treatment group as a measure of efficacy [18 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Male or female > or = 18 years of age;

  2. Histologically proven malignancy;

  3. Documented HLA-A*02 positivity, as determined by a central laboratory;

  4. Disease control (Complete Response (CR), Partial Response (PR), or Stable Disease (SD)) according to Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria or NED in the case of patients who received adjuvant chemotherapy

  5. Patient with disease control or NED expectancy > or = 6 months according to investigator opinion;

  6. ECOG performance status 0, 1;

  7. Patients must have adequate renal and hepatic function as assessed by standard laboratory criteria;

  8. Patients must have adequate haematological function:

  • Platelet count > or = 100 x 109/L;

  • White Blood Cell (WBC) count > or = 2.5 x 109/L;

  • Haemoglobin > or = 90g /L;

  1. Female patients must be of non-child-bearing potential (i.e., women with functioning ovaries who have a documented tubal ligation or hysterectomy, ovariectomy or women who are post-menopausal). Women of child-bearing potential must have a negative urine pregnancy test at baseline and agree to practice adequate contraception for 30 days prior to administration of investigational product, throughout the study treatment period and 30 days after completion of injections;

  2. In the investigator's opinion, the patient is capable and willing to comply with the requirements of the study;

  3. Willing and able to sign a written informed consent.

Exclusion Criteria:

  1. Prior treatment with cancer vaccines;

  2. Treatment with immunotherapy (e.g., interferons, interleukins, Tumor Necrosis Factor (TNF), or biological response modifiers, such as Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) etc) within four weeks prior to the first vaccination;

  3. Treatment with immunosuppressive agents (including corticosteroids) within 2 weeks prior to the first vaccination;

  4. Treatment with any investigational drugs, within 4 weeks prior to the first vaccination;

  5. Autoimmune or immunodeficiency disease that in the opinion of the investigator may compromise the safety of the patient in the study;

  6. Any pre-existing medical condition requiring concomitant systemic corticosteroid or immunosuppressive therapy. The use of inhaled corticosteroids for Chronic Obstructive Pulmonary Disease (COPD) or topical steroids is allowed;

  7. Known hepatitis B and/or C infection documented in patient files, testing not required;

  8. Known HIV-positivity, testing not required;

  9. Clinically significant hepatic dysfunction (Alanine amino transferase (ALT)>2.5 times normal upper limits [ULN], Aspartate Amino Transferase (AST)>2.5 times Upper Limit of Normal (ULN), bilirubin>1.5 times ULN);

  10. Clinically significant renal dysfunction (serum creatinine>1.5 time ULN);

  11. Uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease with unstable angina or myocardial infarction within 6 months before enrolment) or uncontrolled ventricular arrhythmias at the time of enrolment in the study (atrial fibrillation or flutter is acceptable);

  12. Splenectomy or splenic irradiation;

  13. Any infectious condition that, in the opinion of the investigator, could compromise the patient's ability to develop an immune response;

  14. Pregnant or lactating females (female patients of child-bearing potential will undertake pregnancy testing at screening and during study completion/withdrawal visits);

  15. Alcohol or drug dependence;

  16. Requirement of concurrent treatment with prohibited medication (investigational product, other anti-cancer treatments including chemotherapy, non-palliative radiotherapy, biological agents and immunomodulating agents, systemic immunosuppressive agents, including systemic corticosteroids);

  17. The investigator considers the patient unfit for the study as a result of the medical interview, physical examination, or screening investigations.

Contacts and Locations

Locations

Site City State Country Postal Code
1 251 General Airforce Hospital Athens Greece 11525
2 Iaso General Hospital Athens Greece 15562
3 University General Hospital of Heraklion Heraklion, Crete Greece 71110

Sponsors and Collaborators

  • Vaxon Biotech

Investigators

  • Principal Investigator: Katsaounis Panagiotis, MD, PhD, Iaso General Hospital, Athens

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Vaxon Biotech
ClinicalTrials.gov Identifier:
NCT02289196
Other Study ID Numbers:
  • Vx-006-101
First Posted:
Nov 13, 2014
Last Update Posted:
Jun 19, 2019
Last Verified:
Jun 1, 2019
Keywords provided by Vaxon Biotech
Vaccine
Additional relevant MeSH terms:
Neoplasms

Study Results

No Results Posted as of Jun 19, 2019